178 related articles for article (PubMed ID: 25453510)
1. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.
Cierlitza M; Chauvistré H; Bogeski I; Zhang X; Hauschild A; Herlyn M; Schadendorf D; Vogt T; Roesch A
Exp Dermatol; 2015 Feb; 24(2):155-7. PubMed ID: 25453510
[TBL] [Abstract][Full Text] [Related]
2. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.
Nagai M; Vo NH; Shin Ogawa L; Chimmanamada D; Inoue T; Chu J; Beaudette-Zlatanova BC; Lu R; Blackman RK; Barsoum J; Koya K; Wada Y
Free Radic Biol Med; 2012 May; 52(10):2142-50. PubMed ID: 22542443
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial respiration--an important therapeutic target in melanoma.
Barbi de Moura M; Vincent G; Fayewicz SL; Bateman NW; Hood BL; Sun M; Suhan J; Duensing S; Yin Y; Sander C; Kirkwood JM; Becker D; Conrads TP; Van Houten B; Moschos SJ
PLoS One; 2012; 7(8):e40690. PubMed ID: 22912665
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.
Blackman RK; Cheung-Ong K; Gebbia M; Proia DA; He S; Kepros J; Jonneaux A; Marchetti P; Kluza J; Rao PE; Wada Y; Giaever G; Nislow C
PLoS One; 2012; 7(1):e29798. PubMed ID: 22253786
[TBL] [Abstract][Full Text] [Related]
5. Elesclomol induces cancer cell apoptosis through oxidative stress.
Kirshner JR; He S; Balasubramanyam V; Kepros J; Yang CY; Zhang M; Du Z; Barsoum J; Bertin J
Mol Cancer Ther; 2008 Aug; 7(8):2319-27. PubMed ID: 18723479
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II).
Yadav AA; Patel D; Wu X; Hasinoff BB
J Inorg Biochem; 2013 Sep; 126():1-6. PubMed ID: 23707906
[TBL] [Abstract][Full Text] [Related]
7. Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate.
Banerjee K; Basu S; Das S; Sinha A; Biswas MK; Choudhuri SK
Free Radic Res; 2016; 50(4):426-46. PubMed ID: 26733073
[TBL] [Abstract][Full Text] [Related]
8. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Roesch A; Vultur A; Bogeski I; Wang H; Zimmermann KM; Speicher D; Körbel C; Laschke MW; Gimotty PA; Philipp SE; Krause E; Pätzold S; Villanueva J; Krepler C; Fukunaga-Kalabis M; Hoth M; Bastian BC; Vogt T; Herlyn M
Cancer Cell; 2013 Jun; 23(6):811-25. PubMed ID: 23764003
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of the anti-cancer drug elesclomol that forms a redox-active copper chelate as a potential anti-tubercular drug.
Ngwane AH; Petersen RD; Baker B; Wiid I; Wong HN; Haynes RK
IUBMB Life; 2019 May; 71(5):532-538. PubMed ID: 30698324
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II).
Hasinoff BB; Yadav AA; Patel D; Wu X
J Inorg Biochem; 2014 Aug; 137():22-30. PubMed ID: 24798374
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants.
Kluza J; Corazao-Rozas P; Touil Y; Jendoubi M; Maire C; Guerreschi P; Jonneaux A; Ballot C; Balayssac S; Valable S; Corroyer-Dulmont A; Bernaudin M; Malet-Martino M; de Lassalle EM; Maboudou P; Formstecher P; Polakowska R; Mortier L; Marchetti P
Cancer Res; 2012 Oct; 72(19):5035-47. PubMed ID: 22865452
[TBL] [Abstract][Full Text] [Related]
12. The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria.
Modica-Napolitano JS; Bharath LP; Hanlon AJ; Hurley LD
Biomolecules; 2019 Jul; 9(8):. PubMed ID: 31344923
[TBL] [Abstract][Full Text] [Related]
13. Elesclomol-Copper Nanoparticles Overcome Multidrug Resistance in Cancer Cells.
Wang Q; Huang CH; Wibowo FS; Amin R; Shen J; Li F; Babu RJ
ACS Appl Mater Interfaces; 2024 Mar; 16(11):13509-13524. PubMed ID: 38466024
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the cytotoxic implications of metal chelators against melanoma and approaches to improve the cytotoxicity profiles of metal coordinating agents.
Akladios FN; Andrew SD; Parkinson CJ
Biometals; 2016 Oct; 29(5):789-805. PubMed ID: 27389037
[TBL] [Abstract][Full Text] [Related]
15. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II).
Hasinoff BB; Wu X; Yadav AA; Patel D; Zhang H; Wang DS; Chen ZS; Yalowich JC
Biochem Pharmacol; 2015 Feb; 93(3):266-76. PubMed ID: 25550273
[TBL] [Abstract][Full Text] [Related]
16. Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.
Livingstone E; Swann S; Lilla C; Schadendorf D; Roesch A
Exp Dermatol; 2015 Sep; 24(9):709-10. PubMed ID: 25865258
[No Abstract] [Full Text] [Related]
17. The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.
Ahn A; Chatterjee A; Eccles MR
Mol Cancer Ther; 2017 Jun; 16(6):1002-1009. PubMed ID: 28576947
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
19. Synthesis, crystallographic characterization and electrochemical property of a copper(II) complex of the anticancer agent elesclomol.
Vo NH; Xia Z; Hanko J; Yun T; Bloom S; Shen J; Koya K; Sun L; Chen S
J Inorg Biochem; 2014 Jan; 130():69-73. PubMed ID: 24176921
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma.
Morrison BW; Doudican NA; Patel KR; Orlow SJ
Melanoma Res; 2010 Feb; 20(1):11-20. PubMed ID: 19966593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
